Aktis Oncology (AKTS) Stock Price, Quote, News & History | Benzinga

SPY770.17+0.15%QQQ720.83+0.45%BTC/USD83,413.00+0.57%DIA524.22−0.03%GLD378.25+0.16%TLT79.97−0.20%

Aktis Oncology Inc (AKTS) Stock Price, Quote, News & History

AKTSNASDAQ

Trade with Public

Trade with Public

$16.08

0.976.42%

Last update: Oct 20, 6:27 PM

$16.10

0.996.55%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$16.08

Volume / Avg.

2.00 / 361.74K

Day Range

- - -

52 Wk Range

14.72 - 34.19

Market Cap

$895.47M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

29

Short Interest

29.16%

Days to Cover

7.3

Recent Aktis Oncology Inc News

Micron and 15 Other Stocks To Play The AI Buildout Race: They Are Still 20% Below Highs

Bank of America screened its AI baskets for Buy-rated stocks down over 20% from highs. Micron carries the widest gap to target.

Piero Cingari

DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On Tuesday

US stocks were mixed, Nasdaq fell 1%. DigitalOcean shares rose after strong revenue growth and earnings guidance. Other big gainers include CRNX, MAAS, and AGIO.

Avi Kapoor

This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

Top Wall Street analysts changed outlook on top names. For all changes, including upgrades/downgrades, visit analyst ratings page. Consider buying AKTS stock? Analysts weigh in.

Avi Kapoor

Rezolve AI, Bakkt, Seagate And Other Big Stocks Moving Higher On Friday

U.S. stocks were mixed, with the Dow Jones gaining 100 points. Rezolve AI (RZLV) jumped 11.9%, and other stocks such as ALOY and FWRD also rose.

Avi Kapoor

This Hyperfine Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Wednesday

Top analysts change outlook on Hyperfine Inc, Legence, and Aktis Oncology with Buy/Outperform ratings and price targets. See other analysts' views.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-75.29M

Investing Cash Flow (TTM)

-289.39M

Financing Cash Flow (TTM)

336.96M

Free Cash Flow (TTM)

-84.57M

Capital Expenditure (TTM)

-9.27M

Net Change in Cash (TTM)

-27.72M

Analyst Trends and Forecast

1

Jul

2

Aug

1

Sep

1

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.4

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$387.73M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

88.37

PB Ratio (TTM)

1.84

Earnings Yield % (TTM)

-8.23%

Earnings Yield % (FWD)

-16.49%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$8.72

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$82.49M

Debt to Equity

0.02

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-